ABSTRACT
BACKGROUND: Platelet transfusion carries risk of transfusion-transmitted infection (TTI). Pathogen reduction of platelet components (PRPC) is designed to reduce TTI. Pulmonary adverse events (AEs), including transfusion-related acute lung injury and acute respiratory distress syndrome (ARDS) occur with platelet transfusion. STUDY DESIGN: An open label, sequential cohort study of transfusion-dependent hematology-oncology patients was conducted to compare pulmonary safety of PRPC with conventional PC (CPC). The primary outcome was the incidence of treatment-emergent assisted mechanical ventilation (TEAMV) by non-inferiority. Secondary outcomes included: time to TEAMV, ARDS, pulmonary AEs, peri-transfusion AE, hemorrhagic AE, transfusion reactions (TRs), PC and red blood cell (RBC) use, and mortality. RESULTS: By modified intent-to-treat (mITT), 1068 patients received 5277 PRPC and 1223 patients received 5487 CPC. The cohorts had similar demographics, primary disease, and primary therapy. PRPC were non-inferior to CPC for TEAMV (treatment difference -1.7%, 95% CI: (-3.3% to -0.1%); odds ratio = 0.53, 95% CI: (0.30, 0.94). The cumulative incidence of TEAMV for PRPC (2.9%) was significantly less than CPC (4.6%, p = .039). The incidence of ARDS was less, but not significantly different, for PRPC (1.0% vs. 1.8%, p = .151; odds ratio = 0.57, 95% CI: (0.27, 1.18). AE, pulmonary AE, and mortality were not different between cohorts. TRs were similar for PRPC and CPC (8.3% vs. 9.7%, p = .256); and allergic TR were significantly less with PRPC (p = .006). PC and RBC use were not increased with PRPC. DISCUSSION: PRPC demonstrated reduced TEAMV with no excess treatment-related pulmonary morbidity.
Subject(s)
Respiratory Distress Syndrome , Transfusion Reaction , Blood Platelets , Blood Transfusion , Cohort Studies , Humans , Photosensitizing Agents , Platelet Transfusion/adverse effects , Respiratory Distress Syndrome/etiology , Respiratory Distress Syndrome/therapy , Transfusion Reaction/epidemiology , Transfusion Reaction/etiologyABSTRACT
ABSTRACT: Patients treated with antineoplastic therapy often develop thrombocytopenia requiring platelet transfusion, which has potential to exacerbate pulmonary injury. This study tested the hypothesis that amotosalen-UVA pathogen-reduced platelet components (PRPCs) do not potentiate pulmonary dysfunction compared with conventional platelet components (CPCs). A prospective, multicenter, open-label, sequential cohort study evaluated the incidence of treatment-emergent assisted mechanical ventilation initiated for pulmonary dysfunction (TEAMV-PD). The first cohort received CPC. After the CPC cohort, each site enrolled a second cohort transfused with PRPC. Other outcomes included clinically significant pulmonary adverse events (CSPAE) and the incidence of treatment-emergent acute respiratory distress syndrome (TEARDS) diagnosed by blinded expert adjudication. The incidence of TEAMV-PD in all patients (1068 PRPC and 1223 CPC) was less for PRPC (1.7 %) than CPC (3.1%) with a treatment difference of -1.5% (95% confidence interval [CI], -2.7 to -0.2). In patients requiring ≥2 PCs, the incidence of TEAMV-PD was reduced for PRPC recipients compared with CPC recipients (treatment difference, -2.4%; 95% CI, -4.2 to -0.6). CSPAE increased with increasing PC exposure but were not significantly different between the cohorts. For patients receiving ≥2 platelet transfusions, TEARDS occurred in 1.3% PRPC and 2.6% CPC recipients (P = .086). Bayesian analysis demonstrated PRPC may be superior in reducing TEAMV-PD and TEARDS for platelet transfusion recipients compared with CPC recipients, with 99.2% and 88.8% probability, respectively. In this study, PRPC compared with CPC demonstrated high probability of reduced severe pulmonary injury requiring assisted mechanical ventilation in patients with hematology disorders dependent on platelet transfusion. This trial was registered at www.ClinicalTrials.gov as #NCT02549222.
Subject(s)
Platelet Transfusion , Humans , Platelet Transfusion/adverse effects , Female , Middle Aged , Male , Aged , Acute Lung Injury/etiology , Blood Platelets , Prospective Studies , Adult , Thrombocytopenia/etiology , Hematologic Diseases/therapySubject(s)
Multicenter Studies as Topic , Patient Selection , Purpura, Thrombotic Thrombocytopenic/drug therapy , Randomized Controlled Trials as Topic , Rituximab/therapeutic use , ADAMTS13 Protein/blood , ADAMTS13 Protein/deficiency , Adolescent , Adult , Aged , Clinical Protocols , Data Collection , Diagnostic Errors , Female , Humans , Male , Middle Aged , Multicenter Studies as Topic/methods , National Heart, Lung, and Blood Institute (U.S.) , Purpura, Thrombotic Thrombocytopenic/blood , Purpura, Thrombotic Thrombocytopenic/diagnosis , Randomized Controlled Trials as Topic/methods , Research Design , Treatment Outcome , United States , Young AdultABSTRACT
Factor V Leiden (FVL) and prothrombin (PT) G20210A mutations are associated with increased risk of deep venous thrombosis, pulmonary embolism, and obstetric complications. The development of inexpensive and reliable screening methods will assist in defining subpopulations of patients at risk who should undergo testing. We used a method, developed by Abbott Laboratories (Abbott Park, IL), to study 5,000 pregnant women and evaluated the association of obstetric complications with the presence of the FVL and PT G20210A mutations. We found a statistically significant association between FVL and stillbirth. There were also trends toward an association between FVL and placental abruption and between PT G20210A and intrauterine growth retardation. In addition, an association may exist between PT G20210A and preterm delivery for white women. All other parameters studied, including miscarriage and preeclampsia, did not show a statistically significant association with FVL or PT G20210A. These results confirm the association between genetic thrombophilia and selected obstetric complications.
Subject(s)
Factor V/genetics , Pregnancy Complications, Hematologic/diagnosis , Prothrombin/genetics , Thrombophilia/complications , Thrombophilia/diagnosis , Boston/epidemiology , Case-Control Studies , Female , Humans , Immunoenzyme Techniques/methods , Pregnancy , Pregnancy Outcome , Prevalence , Thrombophilia/epidemiologyABSTRACT
Heparin-induced thrombocytopenia (HIT) is a serious complication of heparin therapy. Limited data are available regarding repeat HIT antibody testing after an initial negative test. We conducted a retrospective study to determine the utility of repeat testing. Heparin antibodies were detected using the GTI-PF4 enzyme-linked immunoabsorbent assay, ELISA (GTI Diagnostics, Waukesha, WI). Patients (n = 137) were assigned to one of three groups based upon the initial negative test optical density (OD) range of low = 0-0.132, medium = 0.133-0.267, and high = 0.268-0.399. A pretest clinical score was retrospectively determined using the "4T's" (Thrombocytopenia, Timing of platelet fall, Thrombosis, and the absence of oTher causes of thrombocytopenia). A subsequent positive ELISA was found in 16% (22/137) of patients who underwent repeat testing. Most of these patients had a low pretest clinical score (62%). Four patients had an interval change in the pretest score between the initial negative and subsequent positive tests. Only these four patients developed HIT with thrombosis (HITT). Eighty percent of patients with a high initial negative test OD value had a positive ELISA on repeat testing; however, the initial negative test OD value could not predict whether a patient developed HITT. In contrast, an increase in the pretest clinical probability between initial and repeat testing better predicted HITT. Consecutive repeat ELISA testing for heparin antibodies may be warranted in patients with an increase in their pretest clinical score after an initial negative test as an adjunct to confirm the diagnosis of HIT.
Subject(s)
Anticoagulants/adverse effects , Heparin/adverse effects , Thrombocytopenia/chemically induced , Aged , Aged, 80 and over , Blood Coagulation Tests , Coronary Artery Bypass , Enzyme-Linked Immunosorbent Assay , Female , Heparin, Low-Molecular-Weight/adverse effects , Humans , Male , Middle Aged , Platelet Count , Retrospective StudiesABSTRACT
BACKGROUND: To improve donor management for donor lymphocyte collections, a protocol was established to tailor the amount of whole blood processed during leukapheresis to achieve the requested cellular dose. STUDY DESIGN AND METHODS: A retrospective review of donor and product records of all donors who provided donor lymphocytes during the period October 27, 1999, to March 2, 2005, was performed (25 donors, 54 collections). Data on product total CD3+ T cells collected and total blood volume (TBV) processed were used to establish a correlation between the two variables. The resultant correlation from the reference group (8 donors, 13 collections) was then used to prospectively determine the TBV to be processed in a subsequent series of collections ("prospective group": 18 donors, 41 collections). Donor charts were also reviewed to determine leukapheresis-associated adverse events. RESULTS: The application of the correlation data between TBV processed and CD3+ T-cell yields from the initial reference group to the prospective group yielded 92 percent successful collections; in 3 of the 4 inadequate collections, the predefined maximum of three times their TBV was processed. Compared to the reference group, the TBV processed in the prospective group was decreased from 12,598+/-4007 to 7942+/-5079 mL; the length of procedure was decreased from 208+/-53 to 146+/-79 minutes. Adverse event data were reviewed for 51 collections; the percentage of procedures without adverse events increased from 23 percent in the reference group to 37 percent in the prospective group. CONCLUSION: Application of correlation data between TBV processed and CD3+ T-cell yield was useful to predict efficient and successful donor lymphocyte collections.